Full Press Release Details
InspireMD Announces Participation in
Two Investor Conferences in September
Presenting at Rodman & Renshaw conference
on Tuesday, September 10th
Presenting at Stifel Healthcare conference
on Thursday, September 12th
BOSTON, MA - August 29, 2013 - InspireMD,
Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), today announced that the management team will present
at the following investor conferences:
On Tuesday, September 10th,
Alan Milinazzo, President and Chief Executive Officer of InspireMD, will present at the 15th Annual Rodman & Renshaw
Global Investment Conference at the Millennium Broadway Hotel in New York City. The Company will present at 2:50 pm ET in Room
Investors unable to attend the Rodman
conference may listen in to the webcast, which can be found on the Investors section of the Company's website at www.inspire-md.com/site_en/for-investors/.
The webcast will be available for 90 days following the presentation.
On Thursday, September 12th,
Mr. Milinazzo will present at the Stifel Annual Healthcare Conference at the Four Seasons Hotel in Boston, Massachusetts. The Company
will present at 3:50 pm ET in the Winthrop room.
Investors attending the conferences who
wish to meet with InspireMD management for one-on-one meetings are encouraged to contact their Rodman and Stifel representatives
directly or InspireMD Investor Relations at InspireMD@kcsa.com.
A copy of the materials presented at both
conferences will be available on the InspireMD investor relations website at www.InspireMD.com.
About Stenting and MGuard EPS
Standard stents were not engineered for
heart attack patients. They were designed for treating stable angina patients, whose occlusion is different from that of an occlusion
in a heart attack patient.
In acute heart attack patients, the plaque
or thrombus is unstable and often breaks up as the stent is implanted, causing downstream blockages (some of which can be fatal)
in a significant portion of heart attack patients.
The MGuard EPS is integrated with a precisely
engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage
While offering superior performance relative
to standard stents in STEMI patients with regard to ST segment resolution, the MGuard EPS requires no change in current physician
practice - an important factor in promoting acceptance and general use in time-critical emergency settings.
InspireMD seeks to utilize its proprietary
MGuard technology to make its products the industry standard for embolic protection stents and to provide a superior solution to
the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac
InspireMD intends to pursue applications
of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under
the ticker symbol NSPR.
MGuard EPS is CE Mark approved. It is not
approved for sale in the U.S. by the FDA at this time.
Forward-Looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many
of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks
and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results
or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi)
our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement
by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual
property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the
fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising
may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing
us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with
foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk
factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Transition Report on Form 10-K/T and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future
events or otherwise.
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com